US FDA approves first triptan for teenagers
This article was originally published in Scrip
Executive Summary
The US FDA has approved Almirall's Axert (almotriptan) for a new indication – acute treatment of migraine headache in adolescents (aged 12 to 17 years). This marks the first FDA approval of a triptan migraine treatment for adolescents, the company says.